Our previous cohorts of patients with severe liver diseases allowed us to identify the major risks of a significant decrease in apolipoprotein-A1 (false positives), mainly due to severe hepatic insufficiency and severe fibrosis. This evidence concerns the gene APOA1 and Hepatic failure.